Searching for Anomalous Weak Couplings of Heavy Flavors at the SLC and LEP

The existence of anomalous electric($\tilde \kappa$) and/or magnetic($\kappa$) dipole moment couplings between the heavy flavor fermions ($c,b,\tau$) and the $Z$ boson can cause significant shifts in the values of several electroweak observables currently being probed at both the SLC and LEP. Using the good agreement between existing data and the predictions of the Standard Model we obtain strict bounds on the possible strength of these new interactions for all of the heavy flavors. The decay $Z\rightarrow b\bar b$, however, provides some possible hint of new physics. The corresponding anomalous couplings of $\tau$'s to photons is briefly examined.Comment: 21 pages, 14 figs(available on request), LaTex, SLAC-PUB-667

Can We Observe Weak Anomalous Couplings of Heavy Quarks Through Three Jet Events?

The rates and corresponding jet distributions for the decay $Z\to b\bar bg$ and the process $e^+e^-\to t\bar tg$ may be sensitive to anomalous dipole-like couplings of heavy quarks to the photon and $Z$. In the $b$-quark case, after updating our previous analysis on the constraints imposed by current experiments on $Zb\bar b$ anomalous couplings, we show that the variation of these couplings within their presently allowed ranges leads to rather minor modifications to the Standard Model expectations for $Z\to b\bar bg$ observables. In the $t$-quark case, significant deviations from the Standard Model predictions for $t\bar tg$ production at the Next Linear Collider are possible.Comment: 26 pages with 9 embedded figures; gzipped, uuencoded postscript file. To obtain a copy of this paper send e-mail to [email protected]

Probing Anomalous Chromomagnetic Top Quark Couplings at the NLC

The Next Linear Collider(NLC) will provide a excellent tool for probing the detailed nature of the top quark. By extending the recent analysis of Dokshitzer, Khoze and Sterling, we perform a preliminary examination of the influence of an anomalous chromomagnetic moment for the top, $\kappa$, on the spectrum of gluon radiation associated with $t\bar t$ production. In particular, we analyze the sensitivity of future data to non-zero values of $\kappa$ and estimate the limits that can be placed on this parameter at the NLC with center of mass energies $\sqrt {s}=$ 500 and 1000 GeV.Comment: 15 pages, 12 figures(available on request), LaTex, SLAC-PUB-651

Information and Discrimination from b Quark Production on Z Resonance

We introduce and define operatively in a model independent way a new ``heavy" b-vertexparameter, $\eta_b$, that can be derived from the measurement of a special polarization asymmetry for production of b-quarks on Z resonance. We show that the combination of the measurement of $\eta_b$ with that of a second and previously defined ``heavy" b-vertex parameter $\delta_{bV}$ can discriminate a number of models of New Physics that remain associated to different ``trajectories" in the plane of the variations of the two parameters. This is shown in particular for some popular SUSY and technicolor-type models. In general, this discrimination is possible if a measurement of \underline{both} parameters is performed.Comment: 22 pages, 6 figures available by air mail upon request, (e-mail [email protected] PM/94-04, UTS-DFT-94-02 .( revised version with corrected references

Clinical activity after fingolimod cessation: Disease reactivation or rebound?

Background and purpose: There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods: Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results: A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%) had a relapse within 3 months after fingolimod discontinuation, and an additional 12 (12%) had a relapse within 6 months. According to this study's criteria, 10 patients (10%) had a severe reactivation. Amongst these patients, five (5%) had a reactivation that was considered to be a rebound. Conclusions: The present study showed that more than 26% of patients are at risk of having a relapse within 6 months after fingolimod discontinuation. Nevertheless, the risk of severe reactivations and rebound is lower than has been previously described

Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions

Objective: Single cases and small series of Guillain-Barré syndrome (GBS) have been reported during the SARS-CoV-2 outbreak worldwide. We evaluated incidence and clinical features of GBS in a cohort of patients from two regions of northern Italy with the highest number of patients with COVID-19. Methods: GBS cases diagnosed in 12 referral hospitals from Lombardy and Veneto in March and April 2020 were retrospectively collected. As a control population, GBS diagnosed in March and April 2019 in the same hospitals were considered. Results: Incidence of GBS in March and April 2020 was 0.202/100 000/month (estimated rate 2.43/100 000/year) vs 0.077/100 000/month (estimated rate 0.93/100 000/year) in the same months of 2019 with a 2.6-fold increase. Estimated incidence of GBS in COVID-19-positive patients was 47.9/100 000 and in the COVID-19-positive hospitalised patients was 236/100 000. COVID-19-positive patients with GBS, when compared with COVID-19-negative subjects, showed lower MRC sum score (26.3±18.3 vs 41.4±14.8, p=0.006), higher frequency of demyelinating subtype (76.6% vs 35.3%, p=0.011), more frequent low blood pressure (50% vs 11.8%, p=0.017) and higher rate of admission to intensive care unit (66.6% vs 17.6%, p=0.002). Conclusions: This study shows an increased incidence of GBS during the COVID-19 outbreak in northern Italy, supporting a pathogenic link. COVID-19-associated GBS is predominantly demyelinating and seems to be more severe than non-COVID-19 GBS, although it is likely that in some patients the systemic impairment due to COVID-19 might have contributed to the severity of the whole clinical picture

Constraining Anomalous Top Quark Couplings at the Tevatron

We explore the influence of an anomalous chromomagnetic moment, $\kappa$, onthe production characteristics of top quark pairs at the Tevatron. We find that for top quarks in the 170 GeV mass range, present searches are probing values of $\kappa$ of order ${1 \over 3}$. For $\kappa$'s in this range we find that significant enhancements in the both the $q \bar q,~gg \to t \bar t$ production cross sections are obtained. Once top has been verified and QCD uncertainties are under control, future high statistics measurements at the Tevatron will eventually be sensitive to values of $\kappa$ with magnitudes smaller than 0.10-0.15. We discuss a class of scalar technicolor models which may produce large values of $\kappa$ in conjunction with generation of $m_t$.Comment: LaTex, 16pp, 7 figs (available on request), SLAC-PUB-658

Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study

Chemotherapy-induced peripheral neuropathy (CIPN) lacks standardized clinical measurement. The objective of the current secondary analysis was to examine data from the CIPN Outcomes Standardization (CI-PeriNomS) study for associations between clinical examinations and neurophysiological abnormalities. Logistic regression estimated the strength of associations of vibration, pin, and monofilament examinations with lower limb sensory and motor amplitudes. Examinations were classified as normal (0), moderately abnormal (1), or severely abnormal (2). Among 218 participants, those with class 1 upper extremity (UE) and classes 1 or 2 lower extremity (LE) monofilament abnormality were 2.79 (95% confidence interval [CI]: 1.28-6.07), 3.49 (95%CI: 1.61-7.55), and 4.42 (95%CI: 1.35-14.46) times more likely to have abnormal sural nerve amplitudes, respectively, compared to individuals with normal examinations. Likewise, those with class 2 UE and classes 1 or 2 LE vibration abnormality were 8.65 (95%CI: 1.81-41.42), 2.54 (95%CI: 1.19-5.41), and 7.47 (95%CI: 2.49-22.40) times more likely to have abnormal sural nerve amplitudes, respectively, compared to participants with normal examinations. Abnormalities in vibration and monofilament examinations are associated with abnormal sural nerve amplitudes and are useful in identifying CIPN